Resona Asset Management Co. Ltd. Sells 2,250 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Resona Asset Management Co. Ltd. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,247 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $15,614,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals by 0.4% in the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. Groupama Asset Managment increased its stake in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent analyst reports. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Finally, Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $298.48 on Thursday. The firm has a market cap of $39.85 billion, a PE ratio of 81.55 and a beta of 0.31. The firm’s fifty day moving average is $312.06 and its 200-day moving average is $361.02. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.19 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. Alnylam Pharmaceuticals’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,206 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president owned 64,273 shares in the company, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares in the company, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,255 shares of company stock valued at $6,930,337 in the last quarter. Insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.